I build and lead cross-functional teams of cell and molecular biologists to develop novel gene and RNA therapies. I have track-record expertise in genome and transcriptome editing, cell engineering, genetic and epigenetic programming of human cells, and using pluripotent stem cells in disease modeling. I have been a key early member of four startup R&D teams (two academic labs and two biotechnology start-ups) in building and leading their teams, establishing proofs-of-concept, and creating new therapeutics for preclinical studies.
Well-versed in the culture and manipulation of human pluripotent stem cells (hESCs and IPSCs).
Discovered a novel non-coding RNA and an enhancer that regulates the differentiation of human pluripotent stem cells.
Differentiation of pluripotent stem cells to embryonic and liver lineages for disease modeling, drug screening, and regenerative medicine.
Generation of iPSC cells via Reprogramming of Somatic Cells by RNA vectors.
Phase-separated RNA-protein aggregates in transcriptional activation.
Developed "CUT&RUNER" for the identification of RNA-chromatin interaction.
Identification of RNA-protein interaction by RNA-centric (RAP and ChIRP) and protein-centric (RIP and CLIP) approaches.
Experience in NGS bioinformatics toolsets in the command line environment.
Fluent in R programming for the analysis of biological data (Bioconductor), statistical analysis, and data visualization.
Complete analysis of next-generation sequencing data (ChIP-seq and RNA-seq): sequence alignment, differential transcriptome analysis, and peak calling.
Design and execution of CRISPR/Cas9 experiments in human and murine cells.
Experienced in the use of CRISPRi (KRAB domain) and CRISPRa (VPR) for gene activation and silencing.
Gene silencing by antisense oligos, siRNAs, and lentiviral vectors.
Gene delivery by lentiviral vectors and transposase systems.